Dark Forest Capital Management’s PMV Pharmaceuticals PMVP Stock Holding History

Dark Forest Capital Management’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-106	Closed	-$922	–	1414
2022 Q4	$922	Sell	106 -1,641	-94%	-$17.5K	﹤0.01%	991
2022 Q3	$21K	Buy	1,747 +911	+109%	+$13.2K	﹤0.01%	624
2022 Q2	$12K	Buy	+836	New	+$12.2K	﹤0.01%	508

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dark Forest Capital Management's PMVP Position: Q1 2023 in Review

Dark Forest Capital Management sold out of PMV Pharmaceuticals (PMVP) in Q1 2023, closing a stake of 106 shares — an estimated $922 sold.

Dark Forest Capital Management first reported a position in PMVP in Q2 2022 and held it in 3 quarters. The position peaked at $21K in Q3 2022. 111 funds tracked by Wall St. Rank hold PMVP as of Q1 2023.

Dark Forest Capital Management reported no remaining PMV Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Dark Forest Capital Management sold 106 PMV Pharmaceuticals shares in Q1 2023, an estimated $922.
Dark Forest Capital Management first reported a position in PMV Pharmaceuticals in Q2 2022 and held it in 3 quarters.
Dark Forest Capital Management's PMV Pharmaceuticals position peaked at $21K in Q3 2022.
111 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2023.

Based on Dark Forest Capital Management's 13F filing for Q1 2023, filed 12 May 2023.